Abstract

A POSSIBLE PROMISING AGENTS FOR MANAGEMENT OF COVID-19 - A SYSTEMATIC REVIEW

Amruta A. Chaudhary*, Ashwini V. Shelke and Anil G. Jhadhav

ABSTRACT

An epic coronavirus (CoV), SARS-CoV-2 surfaced in late 2019 in Wuhan, China. SARS-CoV-2, not at all like recently recognized coronaviruses liable for extreme intense respiratory condition (SARS) episode in 2002 and Middle East Respiratory Syndrome (MERS) in 2012, has quickly spread over the globe asserting a great many lives. The new illness brought about by SARS-CoV-2 is named coronavirus malady 2019 (COVID-19) by World Health Organization (WHO). As the SARS-CoV-2 is advancing the world over, specialists and specialists are looking for medications to treat and stop the spread of the ailment. A few medications, for example, hydroxychloroquine/azithromycin, chloroquine, remdesivir Ritonavir/lopinavir and favipiravir are as of now experiencing clinical preliminaries to test their capacity to treat COVID-19 without antagonistic impacts to the tainted patients. Be that as it may, there are numerous other little mixes being accounted from across globe with potential to treat COVID-19 tainted patients worth considering for additional examinations. In this situation, this survey expects to sum up the past, present and future of aggravates that can be utilized to treat crown infection, featuring mixes directly in clinical preliminaries and right to conclusive phases of putting up a medication for sale to the public.

Keywords: SARS-CoV-2, COVID-19, drugs, 2019?CoV, novel coronavirus (nCoV).